Source comparison
Document Tesamorelin + Ipamorelin Blend Research: Comparison
Visceral Fat Reduction (26 weeks) 8–12% mean reduction 4–6% mean reduction 15–20% mean reduction Blend produces 40–60% greater VAT loss than either alone due to dual-pathway GH amplification Lean Mass Preservation Minimal change or slight loss 0.8–1.2kg gain 1
This comparison does not assign a generated winner or score.
- Visceral Fat Reduction (26 weeks)
- 8–12% mean reduction
- 4–6% mean reduction
- 15–20% mean reduction
- Blend produces 40–60% greater VAT loss than either alone due to dual-pathway GH amplification
- Lean Mass Preservation
- Minimal change or slight loss
- 0.8–1.2kg gain
- 1.4–2.1kg gain
- Synergistic effect on muscle protein synthesis, especially under caloric deficit
- Cortisol/Prolactin Elevation
- Minimal
- None
- Ipamorelin's selectivity prevents HPA axis disruption common with older secretagogues
- Insulin Sensitivity (HOMA-IR)
- 10–14% improvement
- 6–9% improvement
- 18–22% improvement
- Visceral fat reduction directly correlates with insulin sensitivity gains
- Injection Frequency
- Daily
- Daily or twice daily
- Daily (single session, dual injection)
- Nocturnal dosing aligns with circadian GH peaks for maximum anabolic signaling
- Reconstituted Stability
- 8 days at 2–8°C
- 28 days at 2–8°C
- Must dose separately; tesamorelin degrades faster
- Mixing in one vial sacrifices tesamorelin potency after day 8